Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

NCT04639843 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Safety issues with PI3 kinase inhibitors

Conditions

Adult T-cell Leukemia/Lymphoma
Extranodal NK-/T-cell Lymphoma, Nasal Type
Enteropathy-Associated T-Cell Lymphoma
Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma
Hepatosplenic T-cell Lymphoma

Interventions

DRUG: CC-486 (5-azacitidine)
DRUG: Duvelisib
DRUG: Romidepsin
DRUG: Doxorubicin

Sponsor

National Cancer Institute (NCI)